Literature DB >> 20690019

F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma.

Ilknur Ak1, Zafer Gulbas.   

Abstract

The percentage of myeloma cells in bone marrow is subsequently an important index of disease in patients with multiple myeloma (MM). Bone marrow myeloma cells can be detected by strong CD38/CD138 positivity and light scatter characteristics using flow cytometry. The aim of the study was to evaluate the relationship between the degree of F-18 fluorodeoxyglucose (F-18 FDG) uptake and the percentage of CD38/CD138 expressing myeloma cells in the bone marrow of patients with MM. A total of 31 patients with MM (14 females and 17 males, mean age 59.5 ± 1.9 years, range 29-80 years) were included in the study. All patients underwent FDG-positron emission tomography/computed tomography (PET/CT) scan within 2 weeks after the completion of the usual staging workup for MM, consisting of X-ray skeletal survey and hematological/biochemical parameters including complete blood count, liver and kidney function test, erythrocyte sedimentation rate, serum immunoglobulins, urine light chain excretion, C-reactive protein, β2-microglobulin, and bone marrow plasma cell infiltration. In all patients, flow cytometry was performed for assessing the percentage of CD38/CD138 expressing myeloma cells in the bone marrow samples. The extent of bone marrow FDG uptake on PET/CT scans was visually graduated using a qualitative scoring system as extension score (E-score) and also a semiquantitative scoring system defined as mean standardized uptake value (mSUV) of both femora. There was a statistically significant positive correlation between the percentage of CD38/CD138 expressing plasma cells in bone marrow and both mean qualitative (r = 0.616) and semiquantitative (r = 0.755) results of F-18 FDG uptakes. mSUV and E-score of bone marrow FDG uptake values were also correlated with serum beta-2-microglobulin levels (r = 0.523 and r = 479, respectively). mSUV of bone marrow FDG uptake values were also negatively correlated with serum albumin levels (r = -0.424), whereas there was no correlation between E-score and albumin levels. In conclusion, our results indicate that increased F-18 FDG uptake of bone marrow is related to the percentage of plasma cell infiltration of bone marrow in patients with MM. Therefore, F-18 FDG-PET/CT study may be a useful tool for predicting the levels of myeloma cells in bone marrow, and an additional analysis of FDG uptake of bone marrow on FDG-PET/CT scans should be performed in patients undergoing PET studies during the initial staging, evaluating the therapy response, and monitoring patients with MM.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20690019     DOI: 10.1007/s00277-010-1037-7

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  7 in total

Review 1.  Imaging of multiple myeloma: Current concepts.

Authors:  Thorsten Derlin; Peter Bannas
Journal:  World J Orthop       Date:  2014-07-18

2.  ImmunoPET imaging of CD38 expression in hepatocellular carcinoma using 64Cu-labeled daratumumab.

Authors:  Shiyong Li; Christopher G England; Emily B Ehlerding; Christopher J Kutyreff; Jonathan W Engle; Dawei Jiang; Weibo Cai
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

3.  CD38 as a PET Imaging Target in Lung Cancer.

Authors:  Emily B Ehlerding; Christopher G England; Dawei Jiang; Stephen A Graves; Lei Kang; Saige Lacognata; Todd E Barnhart; Weibo Cai
Journal:  Mol Pharm       Date:  2017-06-08       Impact factor: 4.939

4.  ImmunoPET imaging of CD38 in murine lymphoma models using 89Zr-labeled daratumumab.

Authors:  Lei Kang; Dawei Jiang; Christopher G England; Todd E Barnhart; Bo Yu; Zachary T Rosenkrans; Rongfu Wang; Jonathan W Engle; Xiaojie Xu; Peng Huang; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-15       Impact factor: 9.236

5.  Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma

Authors:  Arzu Cengiz; Hayri Üstün Arda; Firuzan Döğer; İrfan Yavaşoğlu; Yakup Yürekli; Ali Zahit Bolaman
Journal:  Turk J Haematol       Date:  2018-05-28       Impact factor: 1.831

6.  Computed tomography-based skeletal segmentation for quantitative PET metrics of bone involvement in multiple myeloma.

Authors:  Maria E S Takahashi; Camila Mosci; Edna M Souza; Sérgio Q Brunetto; Cármino de Souza; Fernando V Pericole; Irene Lorand-Metze; Celso D Ramos
Journal:  Nucl Med Commun       Date:  2020-04       Impact factor: 1.698

Review 7.  Metabolic Volume Measurements in Multiple Myeloma.

Authors:  Maria Emilia Seren Takahashi; Irene Lorand-Metze; Carmino Antonio de Souza; Claudio Tinoco Mesquita; Fernando Amorim Fernandes; José Barreto Campello Carvalheira; Celso Dario Ramos
Journal:  Metabolites       Date:  2021-12-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.